The new test is authorised to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours.
offering an end-to-end model, LetsGetChecked's new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution.
The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours.
Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA.
LetsGetChecked's Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing service, including the collection kit manufacturing process, logistics, lab analysis and physician approval, offering a robust system that delivers unmatched safety and scale for customers.
The at-home Coronavirus test is accompanied by LetsGetChecked's connected platform offering 24/7 telehealth services supported by licensed healthcare professionals and timely guidance on containment and care for those who test positive.
The company's at-home Coronavirus (COVID-19) test is designed with safety in mind at every touchpoint.
After a customer self-collects a swab sample, the collection swab is placed in a special transport tube containing a solution that deactivates the virus, ensuring everyone from shipping providers to lab technicians are protected from contamination and infection.
Other tests on the market use a saline solution, which heightens risk by transporting an active virus. The solution also protects the integrity of the SARS-CoV-2 RNA, which heightens accuracy.
With a current capacity of 300,000 units per week, LetsGetChecked's own CLIA/CAP/BSL II certified high complexity laboratory based in Monrovia, California, is building toward a capacity of ms per week in order to meet the demand of partners and individuals in all 50 states.
Prior to the EUA authorisation from the FDA for at-home use, LetsGetChecked has worked with leaders from TODAY's top companies and frontline healthcare workers to offer coronavirus tests to more than 100,000 people.
Most recently, LetsGetChecked partnered with the Professional Golfers Association on the TaylorMade Driving Relief tournament to administer tests both before and during the event, assuring that players, crew, and on-site teams were safe to play for the first televised professional sports event since shutdown.
The company also developed a mobile app with tracking capabilities to monitor all parties' symptoms and temperatures.
This signals LetsGetChecked's pivotal role in providing industries across all verticals a resource to test individuals nationwide and begin re-opening the country.
Tests are received within 24 hours from purchase, with definitive results delivered within 24 hours (of the sample being received by the lab).
LetsGetChecked is a health insights company that allows consumers direct access to a range of testing options and clinical services from home.
Founded in 2015, the company empowers people to take an active role in their health to live longer, happier lives.
By combining health data and diagnostic results, LetsGetChecked provides rich health insights to enable better healthcare decision making.
LetsGetChecked tests cover general health, men's health, women's health, and sexual health, and are available nationwide in the US, Canada, and Europe. LetsGetChecked has corporate offices located in New York City and Dublin.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data